Introduction
CJC-1295 and Ipamorelin are two of the most studied growth hormone secretagogues in peptide research. Frequently examined together due to their complementary mechanisms, these peptides have become reference compounds in preclinical studies on growth hormone release, body composition, and metabolic function.
What Is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It works by binding to GHRH receptors in the pituitary gland, stimulating growth hormone release. Without DAC it has a half-life of approximately 30 minutes. With DAC (Drug Affinity Complex) the half-life extends to 6 to 8 days through albumin binding. Research has shown CJC-1295 produces sustained elevations in plasma GH and IGF-1 levels in animal models through a pulsatile pattern considered more physiologically favorable in research contexts.
What Is Ipamorelin?
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. Unlike GHRP-6 and GHRP-2, Ipamorelin stimulates GH release without significantly elevating cortisol or prolactin in animal studies, making it a cleaner research tool for isolating GH-related effects. It has a short half-life of approximately 2 hours and produces GH pulses that mimic natural physiological release patterns.
Mechanism Comparison
CJC-1295 acts on GHRH receptors, amplifying the magnitude of GH pulses from the pituitary. Ipamorelin acts on ghrelin receptors (GHS-R1a), increasing the frequency of GH pulses. Research combining both peptides has observed synergistic GH release greater than either compound alone, driving interest in their combined use in research protocols.
Research Applications
CJC-1295 research has focused on sustained GH and IGF-1 elevation, lean mass preservation in aging models, and metabolic regulation. Ipamorelin research has concentrated on pulsatile GH release, bone density, fat metabolism, and its favorable selectivity profile compared to other GHRPs.
Stability and Handling
Both peptides are available in lyophilized form and should be reconstituted with bacteriostatic water. CJC-1295 without DAC should be stored at -20°C and used within 4 to 6 weeks of reconstitution. Ipamorelin is similarly stable under standard peptide storage conditions.
Conclusion
CJC-1295 and Ipamorelin represent two complementary tools in GH secretagogue research. CJC-1295 amplifies GH pulse magnitude through GHRH receptor activation while Ipamorelin increases pulse frequency through selective ghrelin receptor agonism. Together they form a foundational pairing in preclinical GH research.